The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lipford, G. B.
Right arrow Articles by Wagner, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lipford, G. B.
Right arrow Articles by Wagner, H.
The Journal of Immunology, 2000, 165: 1228-1235.
Copyright © 2000 by The American Association of Immunologists

CpG-DNA-Mediated Transient Lymphadenopathy Is Associated with a State of Th1 Predisposition to Antigen-Driven Responses1

Grayson B. Lipford2, Tim Sparwasser3, Stefan Zimmermann4, Klaus Heeg4 and Hermann Wagner

Institute for Medical Microbiology, Immunology and Hygiene, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany

Infections can influence concurrent and subsequent Th1 vs Th2 immune responses to Ags. Through pattern recognition of foreign unmethylated CpG dinucleotides, the vertebrate innate immune system can sense infectious danger and typically replies with a Th1-polarized adaptive immune response. We examined whether CpG-DNA exposure would influence subsequent responses to infection and soluble Ags. CpG-DNA injection led to local lymphadenopathy characterized by maintenance of cellular composition with some biasing toward elevated dendritic cell composition. Sustained local production of IL-12 and IFN-{gamma} from dendritic cells and T cells was shown. Prior injection by up to 2 wk with CpG-DNA protected BALB/c mice from Th2 driven lethal leishmaniasis. CpG-DNA injection by up to 5 wk before soluble Ag challenge resulted in the generation of Ag-specific CTL, Th1 recall responses to Ag, and Th1-polarized Ag-specific Abs. Thus, CpG-DNA instigated a local predisposition for intense CTL responses and Th1-polarized immune responses to subsequent infections or Ag challenge. The induction by the innate immune system of a locally contained hypersensitivity could represent a capacitating immune reaction yielding rapid conditioned responses to secondary infections.




This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
R. B. Anderson, G. J. Cianciolo, M. N. Kennedy, and S. V. Pizzo
{alpha}2-Macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism
J. Leukoc. Biol., February 1, 2008; 83(2): 381 - 392.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
A. M. Krieg
Antiinfective Applications of Toll-like Receptor 9 Agonists
Proceedings of the ATS, July 1, 2007; 4(3): 289 - 294.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
F. H. Wikstrom, B. M. Meehan, M. Berg, S. Timmusk, J. Elving, L. Fuxler, M. Magnusson, G. M. Allan, F. McNeilly, and C. Fossum
Structure-Dependent Modulation of Alpha Interferon Production by Porcine Circovirus 2 Oligodeoxyribonucleotide and CpG DNAs in Porcine Peripheral Blood Mononuclear Cells
J. Virol., May 15, 2007; 81(10): 4919 - 4927.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. G. Molenkamp, P. A.M. van Leeuwen, S. Meijer, B. J.R. Sluijter, P. G.J.T.B. Wijnands, A. Baars, A. J.M. van den Eertwegh, R. J. Scheper, and T. D. de Gruijl
Intradermal CpG-B Activates Both Plasmacytoid and Myeloid Dendritic Cells in the Sentinel Lymph Node of Melanoma Patients
Clin. Cancer Res., May 15, 2007; 13(10): 2961 - 2969.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
Z. Wang, L. Xiang, J. Shao, and Z. Yuan
The 3' CCACCA Sequence of tRNAAla(UGC) Is the Motif That Is Important in Inducing Th1-Like Immune Response, and This Motif Can Be Recognized by Toll-Like Receptor 3.
Clin. Vaccine Immunol., July 1, 2006; 13(7): 733 - 739.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. P. A. MacDonald, V. Rowe, H. M. Bofinger, R. Thomas, T. Sasmono, D. A. Hume, and G. R. Hill
The Colony-Stimulating Factor 1 Receptor Is Expressed on Dendritic Cells during Differentiation and Regulates Their Expansion
J. Immunol., August 1, 2005; 175(3): 1399 - 1405.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. A. Mason, H. Ariga, R. Neal, D. Valdecanas, N. Hunter, A. M. Krieg, J. K. Whisnant, and L. Milas
Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy
Clin. Cancer Res., January 1, 2005; 11(1): 361 - 369.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Milas, K. A. Mason, H. Ariga, N. Hunter, R. Neal, D. Valdecanas, A. M. Krieg, and J. K. Whisnant
CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation
Cancer Res., August 1, 2004; 64(15): 5074 - 5077.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Switaj, A. Jalili, A. B. Jakubowska, N. Drela, M. Stoksik, D. Nowis, G. Basak, J. Golab, P. J. Wysocki, A. Mackiewicz, et al.
CpG Immunostimulatory Oligodeoxynucleotide 1826 Enhances Antitumor Effect of Interleukin 12 Gene-Modified Tumor Vaccine in a Melanoma Model in Mice
Clin. Cancer Res., June 15, 2004; 10(12): 4165 - 4175.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
A. Vogt, P.-T. Chuang, J. Hebert, J. Hwang, Y. Lu, L. Kopelovich, M. Athar, D. R. Bickers, and E. H. Epstein Jr.
Immunoprevention of Basal Cell Carcinomas with Recombinant Hedgehog-interacting Protein
J. Exp. Med., March 15, 2004; 199(6): 753 - 761.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Chaput, N. E. C. Schartz, F. Andre, J. Taieb, S. Novault, P. Bonnaventure, N. Aubert, J. Bernard, F. Lemonnier, M. Merad, et al.
Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection
J. Immunol., February 15, 2004; 172(4): 2137 - 2146.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Y.-F. Chen, C.-W. Lin, Y.-P. Tsao, and S.-L. Chen
Cytotoxic-T-Lymphocyte Human Papillomavirus Type 16 E5 Peptide with CpG-Oligodeoxynucleotide Can Eliminate Tumor Growth in C57BL/6 Mice
J. Virol., February 1, 2004; 78(3): 1333 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. R. M. Olbrich, S. Schimmer, and U. Dittmer
Preinfection Treatment of Resistant Mice with CpG Oligodeoxynucleotides Renders Them Susceptible to Friend Retrovirus-Induced Leukemia
J. Virol., October 1, 2003; 77(19): 10658 - 10662.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. E. Oran and H. L. Robinson
DNA Vaccines, Combining Form of Antigen and Method of Delivery to Raise a Spectrum of IFN-{gamma} and IL-4-Producing CD4+ and CD8+ T Cells
J. Immunol., August 15, 2003; 171(4): 1999 - 2005.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
N. B. Ray and A. M. Krieg
Oral Pretreatment of Mice with CpG DNA Reduces Susceptibility to Oral or Intraperitoneal Challenge with Virulent Listeria monocytogenes
Infect. Immun., August 1, 2003; 71(8): 4398 - 4404.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
J. D. Marshall, K. Fearon, C. Abbate, S. Subramanian, P. Yee, J. Gregorio, R. L. Coffman, and G. Van Nest
Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions
J. Leukoc. Biol., June 1, 2003; 73(6): 781 - 792.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. D. Sandler, H. Chihara, G. Kobayashi, X. Zhu, M. A. Miller, D. L. Scott, and A. M. Krieg
CpG Oligonucleotides Enhance the Tumor Antigen-specific Immune Response of a Granulocyte Macrophage Colony-stimulating Factor-based Vaccine Strategy in Neuroblastoma
Cancer Res., January 15, 2003; 63(2): 394 - 399.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Heckelsmiller, K. Rall, S. Beck, A. Schlamp, J. Seiderer, B. Jahrsdorfer, A. Krug, S. Rothenfusser, S. Endres, and G. Hartmann
Peritumoral CpG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors to Cure Established Tumors in a Murine Colon Carcinoma Model
J. Immunol., October 1, 2002; 169(7): 3892 - 3899.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Davila, M. G. Velez, C. J. Heppelmann, and E. Celis
Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment
Blood, September 18, 2002; 100(7): 2537 - 2545.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
E. G. Rhee, S. Mendez, J. A. Shah, C.-y. Wu, J. R. Kirman, T. N. Turon, D. F. Davey, H. Davis, D. M. Klinman, R. N. Coler, et al.
Vaccination with Heat-killed Leishmania Antigen or Recombinant Leishmanial Protein and CpG Oligodeoxynucleotides Induces Long-Term Memory CD4+and CD8+T Cell Responses and Protection Against Leishmania major Infection
J. Exp. Med., June 17, 2002; 195(12): 1565 - 1573.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Gierynska, U. Kumaraguru, S.-K. Eo, S. Lee, A. Krieg, and B. T. Rouse
Induction of CD8 T-Cell-Specific Systemic and Mucosal Immunity against Herpes Simplex Virus with CpG-Peptide Complexes
J. Virol., June 5, 2002; 76(13): 6568 - 6576.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Storni, F. Lechner, I. Erdmann, T. Bachi, A. Jegerlehner, T. Dumrese, T. M. Kundig, C. Ruedl, and M. F. Bachmann
Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles
J. Immunol., March 15, 2002; 168(6): 2880 - 2886.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. Miconnet, S. Koenig, D. Speiser, A. Krieg, P. Guillaume, J.-C. Cerottini, and P. Romero
CpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide
J. Immunol., February 1, 2002; 168(3): 1212 - 1218.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.